{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:48:27Z","timestamp":1769204907515,"version":"3.49.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Cardiovascular Interventions"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The impact of race\/ethnicity on coronary stent outcomes in women is unknown. We compared baseline characteristics, social determinants of health, and 1-year outcomes in female African Americans (AA) and Hispanic\/Latinas (HL) versus white women after coronary everolimus-eluting stent implantation in all-comer patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p>\n              We pooled 1863 women from the PLATINUM Diversity (n=1057 women) and PROMUS ELEMENT PLUS (n=806 women) postapproval studies, with some overlap in study sites. Social determinants of health data were only available for PLATINUM Diversity. The primary end point was 1-year major adverse cardiac events (death, myocardial infarction, or target vessel revascularization). Outcomes were risk adjusted using multivariate Cox regression. The study sample comprised 1417 white (76.1%, reference group), 296 AA (15.9%), and 107 HL (5.7%) women. AA were older, and both AA and HL had more diabetes mellitus and hypertension than white women. AA had larger reference vessel diameters but less lesion calcification, whereas HL had less lesion tortuosity but more calcification. Compared with white women, there was a trend toward higher unadjusted 1-year major adverse cardiac events in AA (12.0% versus 8.0%;\n              <jats:italic>P<\/jats:italic>\n              =0.06) but similar rates in HL (11.0% versus 8.0%;\n              <jats:italic>P<\/jats:italic>\n              =0.32), and after risk adjustment, there were no differences (AA women: hazard ratio, 1.47; 95% CI, 1.00\u20132.17; HL women: hazard ratio, 1.33; 95% CI, 0.71\u20132.44). AA had a 3-fold higher adjusted risk of 1-year myocardial infarction (hazard ratio, 3.45; 95% CI, 1.72\u20137.14;\n              <jats:italic>P<\/jats:italic>\n              =0.01) and increased risk of target vessel revascularization (hazard ratio, 1.82; 95% CI, 1.10\u20132.94;\n              <jats:italic>P<\/jats:italic>\n              =0.02). Independent predictors of major adverse cardiac events included renal disease, prior myocardial infarction, silent ischemia, history of stroke, and multivessel disease.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Race and ethnicity confer heterogeneity in women undergoing everolimus-eluting stent implantation. Despite more comorbidities and less favorable social determinants of health, AA and HL women have similar 1-year major adverse cardiac events to white women, although AA women seem to have a higher risk of 1-year myocardial infarction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical Trial Registration<\/jats:title>\n            <jats:p>\n              URL:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              . Unique identifier: NCT02240810.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circinterventions.118.006918","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T10:37:22Z","timestamp":1554979042000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Impact of Race and Ethnicity on the Clinical and Angiographic Characteristics, Social Determinants of Health, and 1-Year Outcomes After Everolimus-Eluting Coronary Stent Procedures in Women"],"prefix":"10.1161","volume":"12","author":[{"given":"Roxana","family":"Mehran","sequence":"first","affiliation":[{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.M., J.C.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaya","family":"Chandrasekhar","sequence":"additional","affiliation":[{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.M., J.C.)."},{"name":"Box Hill Hospital, Monash University, Melbourne, Australia (J.C.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Davis","sequence":"additional","affiliation":[{"name":"Interventional Cardiology, Baptist Hospital, Little Rock, AR (S.D.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Nathan","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, IL (S.N.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Hill","sequence":"additional","affiliation":[{"name":"Interventional Cardiology, St Bernards Heart and Vascular, Jonesboro, AR (R.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Hearne","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Delmarva Heart Research Foundation, Salisbury, MD (S.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vince","family":"Vismara","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Palmetto Health, Columbia, SC (V.V.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Pyo","sequence":"additional","affiliation":[{"name":"Interventional Cardiology, Stony Brook Medicine and the Cardiac Catheterization Laboratories, Stony Brook University Hospital, NY (R.P.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elie","family":"Gharib","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, CAMC Clinical Trials Center, Charleston, WV (E.G.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafir","family":"Hawa","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, North Kansas City Hospital, MO (Z.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Chrysant","sequence":"additional","affiliation":[{"name":"Department of Cardiology, INTEGRIS Baptist Medical Center, Oklahoma City (G.C.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kandzari","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Piedmont Heart Institute, Atlanta, GA (D.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Underwood","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Boston Scientific Corporation, Marlborough, MA (P.U., D.J.A.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic J.","family":"Allocco","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Boston Scientific Corporation, Marlborough, MA (P.U., D.J.A.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Batchelor","sequence":"additional","affiliation":[{"name":"Interventional Heart Program, Inova Health System, Inova Heart &amp; Vascular Institute, Falls Church, VA (W.B.)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.04.054"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.08.865"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.26606"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2013.07.674"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.10.067"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/2048872616661847"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002089"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22570"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.3802"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.11.043"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV7I1A15"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.02.016"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"e_1_3_4_15_2","unstructured":"U.S. Food and Drug Administration. Evaluation and Reporting of Age- Race- and Ethnicity-Specific Data in Medical Device Clinical Studies: Guidance for Industry and Food and Drug Administration Staff. https:\/\/www.fda.gov\/downloads\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/UCM507278.pdf. Updated September 12 2017. Accessed March 5 2019."},{"key":"e_1_3_4_16_2","unstructured":"National Institutes of Health. NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research. https:\/\/grants.nih.gov\/grants\/funding\/women_min\/guidelines.htm. Accessed March 5 2019."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2010.2469"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.907998"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.11110158"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.01.017"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.11.053"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/nutrit\/nuw024"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e3282ff76ae"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.05.092"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.10.041"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-016-0559-4"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1407273"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.922286"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.02.014"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.115.002621"},{"key":"e_1_3_4_31_2","volume-title":"Paper presented at: the American College of Cardiology meeting","author":"Faggioni M","unstructured":"Faggioni, M. Use of potent P2Y12 inhibitors in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. Paper presented at: the American College of Cardiology meeting, Washington, DC; 2017."},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2010.03.002"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.03.007"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8183.2012.00760.x"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000157732.03358.64"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2017.01.010"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12170-015-0447-4"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31821d98b2"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22213"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)31109-3"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S65528"}],"container-title":["Circulation: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCINTERVENTIONS.118.006918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T02:45:43Z","timestamp":1715568343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCINTERVENTIONS.118.006918"}},"subtitle":["Insights From the Pooled PLATINUM Diversity and PROMUS ELEMENT PLUS Postapproval Studies"],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1161\/CIRCINTERVENTIONS.118.006918"],"URL":"https:\/\/doi.org\/10.1161\/circinterventions.118.006918","relation":{},"ISSN":["1941-7640","1941-7632"],"issn-type":[{"value":"1941-7640","type":"print"},{"value":"1941-7632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"2018-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e006918"}}